Antony A. Riley - 30 Dec 2025 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Issuer symbol: FBRX
Transactions as of: 30 Dec 2025
Net transactions value: +$250,633
Form type: 4
Filing time: 02 Jan 2026, 16:04:43 UTC
Previous filing: 02 Oct 2025
Next filing: 13 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Riley Antony A	CHIEF FINANCIAL OFFICER	C/O FORTE BIOSCIENCES, INC., 3060 PEGASUS PARK DR., BLDG 6, DALLAS	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	02 Jan 2026	0001339375

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FBRX	Common Stock	Purchase	$254,833	+9,680	+30%	$26.33	41,520	30 Dec 2025	Direct	F1
transaction	FBRX	Common Stock	Options Exercise	$0	+375	+0.9%	$0.000000	41,895	01 Jan 2026	Direct	F2
transaction	FBRX	Common Stock	Tax liability	$4,200	-154	-0.37%	$27.27	41,741	01 Jan 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Restricted Stock Units	Options Exercise	$0	-375	-20%	$0.000000	1,500	01 Jan 2026	Common Stock	375		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the weighted average share price of an aggregate total of 9,680 shares purchased in the price range of $26.2243 to $26.59 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
F3	On January 1, 2026, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2025 was the settlement price used to calculate the shares withheld.
F4	Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.